Literature DB >> 10489124

The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas.

H Sugo1, S Takamori, K Kojima, T Beppu, S Futagawa.   

Abstract

The significance of p53 mutations in the primary lesion for recurrent hepatocellular carcinoma (HCC) was evaluated. Mutations of p53 were examined using nonradioisotopic (nonRI)-polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) in 98 resected HCCs. Of the 98 cases, 25 (26%) had a p53 mutation. In 83 patients who survived surgery, the presence of a p53 mutation was associated with a shortened overall survival (P < 0.001) and a shortened cancer-free survival (P < 0.05). In 43 patients who developed recurrence, there was no statistically significant correlation between the status of p53 in the primary lesion and the clinical features of recurrent HCCs examined, i.e., extrahepatic metastasis, the number of recurrent tumors, extent of recurrent tumors, and treatment for recurrent tumors. However, postrecurrence survival was significantly lower in patients in whom a p53 mutation had been detected in the primary lesion (P < 0.01). A multivariate analysis for prognostic value after recurrence revealed that the p53 mutation was a useful independent prognostic factor affecting survival after recurrence (P < 0.01). In conclusion, our findings suggest that HCCs with p53 mutations have a high malignant potential based on their poor prognosis. Therefore, a p53 mutation in the primary lesion is useful as an indicator of the biological behavior of recurrent HCCs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10489124     DOI: 10.1007/BF02482774

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  27 in total

1.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.

Authors:  M Orita; H Iwahana; H Kanazawa; K Hayashi; T Sekiya
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation.

Authors:  S Tanaka; Y Toh; E Adachi; T Matsumata; R Mori; K Sugimachi
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

3.  Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining.

Authors:  T Nagao; F Kondo; T Sato; Y Nagato; Y Kondo
Journal:  Hum Pathol       Date:  1995-03       Impact factor: 3.466

4.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

5.  Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach.

Authors:  M Saegusa; Y Takano; H Kishimoto; G Wakabayashi; K Nohga; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.

Authors:  H C Hsu; H J Tseng; P L Lai; P H Lee; S Y Peng
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

7.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

8.  Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma.

Authors:  K Ikeda; S Saitoh; A Tsubota; Y Arase; K Chayama; H Kumada; G Watanabe; M Tsurumaru
Journal:  Cancer       Date:  1993-01-01       Impact factor: 6.860

9.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.

Authors:  J Bergh; T Norberg; S Sjögren; A Lindgren; L Holmberg
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

10.  Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes.

Authors:  Y Kakeji; D Korenaga; S Tsujitani; H Baba; H Anai; Y Maehara; K Sugimachi
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

View more
  14 in total

Review 1.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

2.  Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinomatous and pericarcinomatous tissues.

Authors:  Zhao-Shan Niu; Bo-Kian Li; Mei Wang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

3.  Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.

Authors:  Dénes Görög; János Regöly-Mérei; Sándor Paku; László Kopper; Péter Nagy
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

4.  P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.

Authors:  Lun-Xiu Qin; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Xin-Da Zhou; Qing-Hai Ye; Yuan Ji; Li-Wen Huang; Hu-Liang Jia; Hui-Chuan Sun; Lu Wang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

Review 5.  The prognostic molecular markers in hepatocellular carcinoma.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds.

Authors:  Xiaohui Duan; Yi Cai; Tingting He; Xiaoliang Shi; Juan Zhao; Hui Zhang; Yao Shen; Hongjian Zhang; Heng Zhang; Wenbin Duan; Bo Jiang; Xianhai Mao
Journal:  J Gastrointest Oncol       Date:  2021-08

7.  TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-10       Impact factor: 7.293

Review 8.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

9.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Ju-Yann Wu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

10.  Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus.

Authors:  Chuangye Han; Tingdong Yu; Wei Qin; Xiwen Liao; Jianlu Huang; Zhengtao Liu; Long Yu; Xiaoguang Liu; Zhiwei Chen; Chengkun Yang; Xiangkun Wang; Shutian Mo; Guangzhi Zhu; Hao Su; Jiaquan Li; Xue Qin; Ying Gui; Zengnan Mo; Lequn Li; Tao Peng
Journal:  J Gastrointest Oncol       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.